TLDR
- Tharimmune (THAR) stock surged 207% Wednesday and another 46.8% pre-market Thursday following positive simulation results for TH104
- TH104 is a buccal film drug designed to prevent fentanyl and opioid effects with 30-minute onset and 24-hour protection
- The drug significantly outperforms naloxone, which only provides 30-90 minutes of protection
- TH104 targets military personnel and first responders at risk of weaponized fentanyl exposure
- Stock has traded between $0.95-$6.39 over 52 weeks and is up 77% year-to-date
Tharimmune stock exploded Wednesday, climbing 207% before adding another 46.8% in pre-market trading Thursday. The clinical-stage biotechnology company’s shares rocketed after announcing positive pharmacokinetic simulation results for its lead candidate TH104.
The biotech firm released data showing TH104 could revolutionize opioid overdose prevention. TH104 is a thin buccal film placed in the mouth that delivers nalmefene, an experimental drug designed to block fentanyl and other powerful opioids.01
The simulation results revealed TH104 begins working within 30 minutes. More importantly, the drug provides protection for approximately 24 hours. This extended duration represents a major breakthrough compared to existing treatments.
Current options like naloxone typically work for only 30 to 90 minutes. This short window often requires multiple doses and constant monitoring. TH104’s extended protection could eliminate these limitations.
Game-Changing Protection Window
The 24-hour protection window sets TH104 apart from all current treatments. Military personnel and first responders face unique risks from weaponized fentanyl exposure. These groups need preventive treatments they can take before potential exposure.
TH104 addresses this critical gap in current medical countermeasures. The drug could protect high-risk personnel from the rapid respiratory depression caused by powerful opioids. This protection extends to the nervous system effects that make fentanyl particularly dangerous.
Pharmacokinetic simulation helped researchers predict how TH104 moves through the body. The process examines absorption, distribution, breakdown, and elimination without full human testing. This approach allows faster development while maintaining safety protocols.
Stock Performance and Volatility
THAR shares have experienced extreme volatility over the past year. The stock has traded in a wide range between $0.95 and $6.39 during the 52-week period. Year-to-date performance shows gains of 77% even before this week’s surge.
However, the five-year picture tells a different story. THAR stock has declined nearly 100% over that extended timeframe. This reflects the typical boom-bust cycle common in biotech stocks.
The company focuses on developing treatments for inflammatory and immune-related conditions. TH104 represents their most advanced clinical candidate currently in trials. The positive simulation results mark a crucial milestone in the drug’s development path.
Wednesday’s trading volume spiked as investors digested the news. After-hours trading added another 42% gain to Wednesday’s massive move. Thursday’s pre-market surge continued the momentum with the additional 46.8% increase.
The latest results position Tharimmune as a potential solution to the ongoing opioid crisis. Weaponized fentanyl represents a national security concern due to its extreme potency. Mass casualty events remain a real threat if these substances are used as weapons.
TH104’s extended protection window and rapid onset could provide critical defense capabilities. Military units and emergency responders would benefit from advance protection rather than reactive treatment. This preventive approach could save lives in high-risk scenarios.
The simulation data showed TH104 maintains effective drug levels throughout the 24-hour period. This consistent protection eliminates the need for frequent redosing. Healthcare providers could administer the treatment once per day rather than multiple times.
Thursday’s pre-market gains brought THAR stock near its 52-week high of $6.39.
Stay Ahead of the Market with Benzinga Pro!
Want to trade like a pro? Benzinga Pro gives you the edge you need in today's fast-paced markets. Get real-time news, exclusive insights, and powerful tools trusted by professional traders:
- Breaking market-moving stories before they hit mainstream media
- Live audio squawk for hands-free market updates
- Advanced stock scanner to spot promising trades
- Expert trade ideas and on-demand support
